On July 2, Alibaba Health rose 3.57% at open, trading at HK$3.19 per share, with turnover of HK$2.5137 million.

On the news front, Hengrui Medicine's Class 1 innovative drug Ruiming (China's first domestically developed high-selectivity URAT1 inhibitor for gout with hyperuricemia) and Yangtze River Pharmaceutical's Class 1 new drug Taitutuo (a next-generation PDE5 inhibitor for erectile dysfunction) both launched exclusively on Alibaba Health on June 29. The simultaneous selection of Alibaba Health as the online exclusive first-launch channel by two blockbuster innovative drugs validated the company's channel value and digital service capabilities in innovative drug commercialization, reinforcing its strategic positioning as a first-launch platform for new specialty drugs.

Management previously guided fiscal year 2027 revenue growth of 10% to 15% year-over-year, with innovative drug categories identified as the core growth driver. Multiple investment banks including Bank of America and Jefferies maintain Buy ratings on the stock, citing long-term industry digitalization opportunities and the company's integrated B2C and O2O positioning.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)